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Abstract
Background: Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for
preventing severe rotavirus diarrhea. New data suggest vaccine efficacy may vary by region.
Methods: We reviewed published vaccine efficacy trials to estimate a regional-specific effect of vaccine efficacy on
severe rotavirus diarrhea and hospitalizations. We assessed the quality of evidence using a standard protocol and
conducted meta-analyses where more than 1 data point was available.
Results: Rotavirus vaccine prevented severe rotavirus episodes in all regions; 81% of episodes in Latin America,
42.7% of episodes in high-mortality Asia, 50% of episodes in sub-Saharan Africa, 88% of episodes low-mortality Asia
and North Africa, and 91% of episodes in developed countries. The effect sizes observed for preventing severe
rotavirus diarrhea will be used in LiST as the effect size for rotavirus vaccine on rotavirus-specific diarrhea mortality.
Conclusions: Vaccine trials have not measured the effect of vaccine on diarrhea mortality. The overall quality of
the evidence and consistency observed across studies suggests that estimating mortality based on a severe
morbidity reduction is highly plausible.
Background
Diarrhea remains the second leading cause of death
around the world for children under 5 years of age [1].
Because the majority of diarrhea deaths occur in the low
and middle-income countries, the etiologic agents
responsible for diarrhea deaths among young children
are unknown. Using hospitalization data as a best esti-
mate of severe diarrheal disease and a proxy for diarrhea
mortality, it has been estimated that rotavirus may be
responsible for up to 39% of child deaths, the majority
of which occur in low and middle income countries [2].
Several rotavirus vaccines have been introduced in the
US market since the late 1990s. The current vaccines
include a monovalent attenuated human rotavirus vac-
cine and a pentavalent human-bovine reassortant vac-
cine. Previous reviews, including a Cochrane review and
a systematic review recently published by our group
have quantified the pooled efficacy of these vaccines on
severe diarrheal disease as well as diarrhea mortality
among children in developed countries and a selected
group of Latin American middle-income countries [3,4].
Until recently, data from trials in sub-Saharan Africa
and Asia had not been published and thus not yet
included in meta-analyses of published effect sizes [5-8].
With the publication of the final results from trials in
sub-Saharan Africa and Asia, it is critical to re-evaluate
the evidence to date. The Lives Saved Tool (LiST)u s e s
v a c c i n ee f f i c a c yt om o d e lt h et o t a ll i v e st h a tc o u l db e
saved with introduction and scale up of rotavirus vac-
cine in low- and middle-income countries. Because new
data suggest substantial variation in vaccine efficacy by
region, we estimate regional-specific vaccine efficacy on
rotavirus mortality to be used in program planning by
incorporation into LiST.
Methods
We previously conducted and published the results of a
systematic review to identify studies assessing the effect
of rotavirus vaccine on diarrhea incidence and mortality
using the guidelines established by the Child Health
Epidemiology Reference Group (CHERG) [3,9]. In brief,
we conducted a literature search to indentify all Phase
III rotavirus vaccine trials of marketed products as of
January 2009. We reviewed more than 400 titles and
abstracts, screened 17 full papers and included 5 papers
* Correspondence: cfischer@jhsph.edu
Department of International Health, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD, 21205, USA
Fischer Walker and Black BMC Public Health 2011, 11(Suppl 3):S16
http://www.biomedcentral.com/1471-2458/11/S3/S16
© 2011 Fischer Walker and Black; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.in our final review. Since this review [5-8], 4 studies
have been published providing additional data for Asia
and sub-Saharan Africa, where previous data were not
available.
We screened the newly published studies according
to our original inclusion and exclusion criteria and
abstracted key variables according to the CHERG
adapted GRADE technique (Grading of Recommenda-
tions Assessment, Development and Adaptation) [10]
for each of the following study outcomes: rotavirus
hospitalizations, all diarrhea hospitalizations, incidence
of rotavirus infections, and incidence of severe all-
cause diarrhea infections (Additional File 1) [9]. For
this analysis we excluded studies that included children
who received less than the recommended vaccine dose.
Many of the pivotal studies led to multiple publica-
tions; we abstracted data from all publications (Addi-
tional File 1) but included only the data from the
papers reporting the full 2 years of follow-up in our
final meta-analysis. In some cases this was a smaller
sub-group analysis, however these data were chosen
because the final vaccine effect size will be applied to
children beyond the first 12 mo of life. Likewise, in
order to provide a better measure of the potential
impact of the vaccine when implemented under rou-
tine conditions, we abstracted intent-to-treat data from
case control studies. In a standardized summary table
we described the overall quality of evidence and sum-
marize the input data for rotavirus hospitalization and
incidence of severe rotavirus infection as the best mea-
sures of serious rotavirus morbidity. For each outcome
we grouped evidence into 5 distinct country groupings:
developed, Latin America, low mortality Asia and
North Africa, high mortality Asia, and sub-Saharan
Africa (Table 1).
For outcomes and regions where more than one study
had data available, we preformed both fixed and random
effect meta-analyses using STATA statistical software.
We reported the Mantel-Haenszel pooled relative risk
and corresponding 95% confidence interval (CI).
Results
We identified 2 studies in the Latin America region
[11,12], 2 studies from sub-Saharan Africa [5,6], 1 study
from the high mortality Asian countries [7], 2 studies
with data from low mortality Asian and North African
countries [7,8], and 2 studies from developed countries
[13,14] (Additional File 2). In Latin America, 1 study
reported that rotavirus vaccine prevented 81% of cases
of severe rotavirus and in high-mortality Asia, 1 study
reported that rotavirus vaccine prevented 42.7% of
severe rotavirus episodes. For the regions of sub-Saharan
Africa, low-mortality Asia and North Africa, and devel-
oped countries we conducted meta-analyses for the
Table 1 Countdown to 2015 and GAVI eligible countries
by under 5 mortality rate and region for use in applying
rotavirus vaccine effect size
Region/Country < 5
Mortality Rate
Region/Country < 5
Mortality Rate
Developed Sub-Saharan Africa
Cuba 6 Eritrea 55
Ukraine 15 Botswana 57
Armenia 22 Madagascar 57
Moldova 17 South Africa 62
Low mortality Asia
and North Africa
Ghana 68
China 19 Gabon 69
Sri Lanka 15 Swaziland 73
Egypt 21 Sao Tome and
Principe
78
Vietnam 23 Lesotho 82
Latin America Kenya 84
Mexico 17 Zimbabwe 86
Brazil 21 Djibouti 93
Peru 21 Senegal 93
Nicaragua 25 Togo 96
Honduras 29 Comoros 102
Guyana 35 Gambia 102
Guatemala 40 Ethiopia 104
Bolivia 50 Tanzania 105
Haiti 86 Sudan 108
High mortality Asia Liberia 110
Georgia 29 Malawi 110
Mongolia 29 Rwanda 111
DPR Korea 33 Cote d’Ivoire 115
Philippines 33 Mauritania 115
Azerbaijan 34 Benin 117
Uzbekistan 35 Congo 125
Solomon Islands 36 Uganda 127
Kyrgyzstan 37 Nigeria 138
Morocco 37 Mozambique 139
Indonesia 39 Guinea 140
Iraq 44 Zambia 141
Turkmenistan 45 Equitorial Guinea 147
Kiribati 46 Cameroon 150
Nepal 48 Niger 156
Bangladesh 52 Angola 161
Timor Leste 56 Burundi 165
Laos 58 Burkina Faso 166
Tajikistan 61 CAR 168
India 66 Somalia 179
Papua new
guinea
66 Mali 191
Yemen 66 Sierra Leone 191
Myanmar 71 Guinea-Bissau 192
Bhutan 79 DR Congo 193
Pakistan 85 Chad 208
Cambodia 87
Afghanistan 192
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tis and estimated that rotavirus vaccine prevented 50%
of severe rotavirus episodes in sub-Saharan Africa
(Figure 1), 88% of severe rotavirus episodes in low-mor-
tality Asia and North Africa (Figure 2), and 91% of severe
rotavirus episodes in developed countries (Figure 3).
At the country level the effect of vaccine on severe rota-
virus disease appears to be directly correlated with
under 5 mortality in that countries with higher under 5
mortality rates have demonstrated lower vaccine efficacy
(Figure 4). The only outcome with data from all regions
was efficacy against severe rotavirus gastroenteritis; in
addition, where hospitalization data were available the
effect against severe rotavirus diarrhea was more conser-
vative than the effect again rotavirus hospitalizations
thus we chose to use the effect of the vaccine on inci-
dence of severe rotavirus disease as the proxy for rota-
virus mortality (Figure 5). Region specific estimates
ranging from 42.7% for high-mortality Asian countries
to 90.6% for developed countries will be incorporated
into LiST for the effect of rotavirus vaccine on rotavirus
specific mortality.
Discussion
In this review we present the first analysis of all rota-
virus vaccine efficacy studies published for the currently
recommended rotavirus vaccines with the intent of esti-
mating region specific effect of the rotavirus vaccine on
diarrhea mortality. We initially abstracted data on all
diarrhea outcomes included in the publications. How-
ever, in this analysis we sought to estimate the effect of
rotavirus vaccine on diarrhea mortality thus focused on
the most severe study outcomes as the best proxy for an
anticipated mortality reduction where mortality data are
lacking. Studies measured reductions in severe rotavirus
disease and rotavirus hospitalizations; we chose a final
effect size based on reduction in severe rotavirus inci-
d e n c ea st h i so u t c o m ew a sm e a s u r e di na l lg e o g r a p h i c
regions and was consistently the more conservative esti-
mate as compared to reductions in rotavirus hospitaliza-
tions. Though vaccine trials have not directly measured
the effect of vaccine on diarrhea mortality, two recent
studies in Brazil and Mexico have shown marked reduc-
tions in diarrhea mortality in communities that achieved
high rates of rotavirus vaccination [15,16]. For these rea-
sons, we believe the overall quality of the evidence and
consistency observed across studies suggests that esti-
mating mortality based on a severe morbidity reduction
is highly plausible.
Vaccine trials to date have been focused on severe
diarrhea and thus have not included outcome measures
to capture the effect of vaccine on diarrhea incidence of
any severity. For this reason the LiST model does not
include the effect of rotavirus vaccine on diarrhea inci-
dence. Though it is expected that the rotavirus vaccine
would have a small effect on all cause diarrhea inci-
dence, there are no data to suggest the size of this effect
[17]. Because the effect of vaccine on mortality is cap-
tured here, the small additional benefit via the diarrhea
incidence pathway would be negligible in the model.
In this analysis we only included studies that assessed
efficacy or effectiveness among fully vaccinated children.
In our previous review we included two case control
studies that categorized a child as vaccinated if he/she
had received only 1 dose of vaccine [18,19]. The goal of
LiST is to provide accurate estimates of an anticipated
effect of an intervention on cause-specific mortality at a
given coverage point. Because rotavirus vaccine coverage
indicators are designed to measure the proportion of
children who received the full vaccine dose, we esti-
mated the effect size here including only fully vaccinated
children to ensure consistency. We have not attempted
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Figure 1 Forest plot for the effect of rotavirus vaccine as compared to placebo on severe rotavirus gastroenteritis among children living in sub-
Saharan Africa.
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Page 3 of 7to capture any additional effect the vaccine may have
with regard to population level herd immunity; studies
to date have not been designed to capture this and thus
a possible effect is impossible to quantify.
There are numerous hypotheses as to why the pro-
tective efficacy of the vaccine varies by region and
study population with markedly lower protective effi-
cacy rates in populations with high infant mortality.
Some reasons may include variation in host response
due to passive immunity via breastfeeding or underly-
ing nutritional differences; differences in rates of severe
disease; and variation in endemic disease versus seaso-
nal peaks. It is also possible that bacteria and other
viruses may remain important causes of severe morbid-
ity in low-income settings as compared to children in
high-income settings where improvements in water
and sanitation have virtually eliminated these patho-
gens from the community setting. Co-infection with
more than one potential pathogen in these settings is
common and it is possible that the rotavirus found by
sensitive assays in the stool is not always the organism
causing the illness. The frequent encounter with fecal
pathogens may also lead to “environmental enterpathy”
which, while protecting the child to some degree from
falling repeatedly ill due to routine pathogens, this may
also create a hostile environment for eliciting a lower
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Figure 2 Forest plot for the effect of rotavirus vaccine as compared to placebo on severe rotavirus gastroenteritis among children
living in low mortality* Asian and North African countries * Low mortality defined as countries with an under 5 mortality rate less than 25
per 1000 live births.
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Figure 3 Forest plot for the effect of rotavirus vaccine as compared to placebo on severe rotavirus gastroenteritis among children
living in developed* countries * Developed countries defined as countries in the North American and European regions with an under 5
mortality rate less than 25 per 1000 live births.
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Page 4 of 7immune response to the vaccine [20]. There is also
limited evidence to suggest that substantial variation in
strains included in the vaccine and subsequent circu-
lating stains in the community may cause lower effec-
tiveness in the community, quantifying the effect
o ft h i sv a r i a t i o na c r o s ss e t t i n g si sd i f f i c u l t[ 2 1 ] .
Unfortunately, the appropriate studies have not been
done to determine which, if any, of these hypotheses
explains the observed differences. Additional descrip-
tive etiology studies are needed to more fully under-
stand the role of various pathogens; including
differences in rotavirus strains in causing severe
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Figure 4 Country level* vaccine efficacy against severe rotavirus diarrhea incidence and 2009 under five mortality * Country level data
used when possible. Linhares et al, Vesikari et al (2006 & 2007) and Phua et al do not provide country level data. For these papers we present
overall vaccine efficacy and median under 5 mortality rate for countries included in analysis.
Application of CHERG Rule s 5 and 6￿
Strong evidence of serious morbidity reduction:  Highly plausible
 Latin America  (n=1; 10 Latin American  
countries) 193events  
Africa (n=2; 5 African countries)  
304 events 
High mortality Asia (n=1; 1 country) 
89 events 
Low mortality Asia and North Africa 
(n=2; 4 countries) 73 events 
Developed Countries (n=2; 7 countries) 
224 events 
81% (71.3 – 87.1%) 
49.7% (22.8-67.1%) 
Region    Final Effect Size 
Relative Reduction (95% CI) 
42.7% (10.4 – 63.9%) 
87.9% (4.7 – 98.5%) 
90.6% (85.9-93.7%) 
Figure 5 Final effect sizes for severe rotavirus gastroenteritis as a proxy for rotavirus specific mortality by region.
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genicity, i.e. the likelihood of individual pathogens to
cause disease. Understanding why protective efficacy
varies by population is critical to improve upon the
currently available vaccine or to enhance the individual
effect of the vaccine within different populations.
Despite the reduced effect size observed in low-
income populations, the rotavirus vaccine may still
reduce rotavirus mortality by 50%, an important bene-
fit for some of the world’s most vulnerable children.
Rotavirus vaccine can be delivered on the routine
immunization schedule providing an opportunity to
prevent morbidity and mortality in areas where care
seeking behaviors for diarrhea are not ideal. Preventing
diarrhea mortality needs a multi-prong approach. We
have numerous preventive and treatment tools, includ-
ing rotavirus vaccine and oral rehydration and zinc for
management of illness. Countries and international
organizations need to prioritize control of diarrheal
mortality as part of a comprehensive child survival
strategy.
Conclusions
There is strong evidence suggesting that rotavirus vac-
cine decreases rotavirus specific mortality and thus all
diarrhea mortality in all regions of the world. Though
the effect size appears to be greater among children liv-
ing in developed countries as compared to low-income
countries, the increased risk of diarrhea mortality is
greater in developing countries therefore increasing the
justification for the continued promotion of this impor-
tant child survival tool.
Additional material
Additional File 1: is an excel file and contains details of all of the
studies that were abstracted, including issues related to study
design and quality of data as it relates to the question of interest.
Additional File 2: is an excel file and provides a summarizes the
quality assessment of rotavirus vaccine trials.
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